07:26 AM EST, 03/05/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) has agreed to acquire Chimerix ( CMRX ) for $8.55 per share in cash, representing a total consideration of about $935 million, the companies said Wednesday.

The deal consideration reflects a roughly 72% premium based on the company's closing trading price Tuesday.

Upon the successful completion of its tender offer, Jazz will acquire all Chimerix ( CMRX ) shares not acquired in the tender via a second-step merger, the companies said.

The deal is expected to close in Q2.

Chimerix ( CMRX ) shares were up 4.6% in recent premarket activity, while Jazz rose 0.1%.